Opioid-Induced Constipation Is a Disease, Not a Side Effect

He is fifty-six, nine years into an opioid prescription for a back that has been operated on twice. The dose has gone up four times and the pain score has not moved. What changed is his bowel: two hard-won stools a week, no food before leaving the house, a bottle of magnesium citrate riding in the car. His chart lists that under side effects. Opioid-induced constipation belongs on the problem list instead, and the evidence explains why.

The video The Pain Pill That Paralyzes Your Gut tells his story. Here the job is the evidence underneath it and what a pain practice does with it. The argument is drawn from The Angry Gut, by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, where the gut is the first brain and the skull holds the second, tethered by the vagus nerve.

A side effect is a price accepted for relief; a disease gets treated. Filed in the wrong column, his bowel has steered his care for nine years.

The bowel was built with the receptor already installed

A systemic opioid is aimed at pain circuits in the second brain, but it binds wherever its receptor sits. In the human gut, the mu-opioid receptor sits on neurons in both nerve networks of the bowel wall, on immune cells just under the lining, and on both halves of the peristaltic reflex. The gut already runs on a quiet opioid signal of its own, enkephalin. A prescription turns that volume all the way up.

The effect reaches the whole tube. Three days of oral codeine in healthy volunteers stretched stomach emptying half-time to 144.0 minutes from 95.5, and cut colonic filling at six hours to 11.0% from 51%. Higher up, 24% of 225 chronic users showed esophageal dysfunction, climbing with the strength of the drug from 12% on tramadol to 28% on hydrocodone and 31% on oxycodone.

Then the asymmetry that makes it chronic. Tolerance develops to the pain relief, which is why doses creep up. It does not develop to the bowel effect. Every increase meant to chase an adapting pain lands on a gut that never adapts.

Why so many patients never mention it

In a European study of 1,200 people with cancer pain on opioids, 59.5% met the Rome IV criteria for opioid-induced constipation, yet only 61.5% of them described themselves as constipated. Roughly four in ten with a measurably stalled bowel would not have raised it. Of those given a prescription, only 66% took it every day.

A survey of 322 people already taking both an opioid and a laxative found 81% still constipated and 45% passing fewer than three stools a week. A third had skipped, reduced or stopped their opioid in order to have a bowel movement. They are running an unsupervised taper that nobody charts.

The economics explain the silence. A short visit rewards the fastest tool, and a stool softener takes seconds to add. The question that uncovers the problem takes minutes. The social cost compounds it, and isolation is itself an inflammatory state that feeds pain.

Which drugs and doses weigh most on the bowel

Across 80,475 patients treated for non-cancer pain in Northwest England, severe constipation risk varied by agent. Measured against codeine, fentanyl came in at a hazard ratio of 1.37, oxycodone at 1.46 and morphine at 1.59, while tramadol sat lower than codeine at 0.80. Combination products sat highest of all, at 1.85.

The dose curve bent in an odd direction. Compared with under 50 MME a day, the band from 50 to under 120 carried a hazard ratio of 1.95, while 120 and above came in lower at 1.45. Likely reason: the highest-dose patients get preventive laxatives and closer monitoring. The endpoint counted only in-hospital enemas or suppositories, so the burden at home is larger.

Treating the receptor instead of the stool

If constipation were simply the cost of analgesia, blocking the receptor would cost pain control. Peripherally acting mu-opioid receptor antagonists, called PAMORAs, block the receptor in the bowel without reaching the brain. In two identical phase 3 trials, naldemedine produced responders in 47.6% against 34.6% on placebo, and 52.5% against 33.6%.

The bar for a responder was high: at least three spontaneous bowel movements a week, up by at least one from baseline, for 9 of the 12 weeks. Overall adverse events matched placebo, but gut-specific ones roughly doubled, 40 against 18 in one trial, as a bowel held down for months woke up. Across 27 trials and 9,149 patients, naloxone and naldemedine ranked most effective, cutting the risk of non-response to 0.65 and 0.66.

Two cautions keep this honest. Those trials reported bowel movements, not pain scores, so preserved analgesia rests on how the drugs are designed more than on a measured endpoint. And the class is not a loophole: alvimopan was restricted to hospital use after an association with heart attacks, and in opioid-naive volunteers the approved 25 mg dose of naloxegol did not restore codeine-slowed transit.

Compare the usual reflex. Lubiprostone, which pulls water into the stool, beat placebo on bowel movements, 27.1% against 18.9%, moved no quality-of-life measure, and caused abdominal pain in 7.1% against 0%. The 2023 Japanese guidelines now name naldemedine a primary treatment option, because a laxative treats the stool while the receptor is the problem. Whether a blocker fits your situation is a decision for the physician managing your pain.

When more medication means more pain

The deeper problem is central. Narcotic bowel syndrome is abdominal pain that worsens despite steady or rising doses of the opioid prescribed for it. It develops in roughly 6% of people on long-term narcotics and is thought to arise in the central nervous system, separate from the constipation itself.

The broader pattern has been measured. Across 27 randomized trials and 1,630 surgical patients, higher intraoperative opioid doses led to slightly worse pain afterward, more rescue morphine, and skin more sensitive to pressure. The gap was small and the certainty low. The direction is what matters. Run the other way, a systematic review of 67 studies of dose reduction found every fair-quality study that measured them reporting better pain (8 of 8), better function (5 of 5) and better quality of life (3 of 3), graded very low certainty. Medication-driven pain has a name and a workup.

Our position is that the stalled bowel feeds metaflammation, and metaflammation amplifies the central pain signal. That bridge rests on tissue and animal work; no human trial has run it end to end, because trials exclude the patient with diabetes, depression and a nine-year prescription. Every step of the plan below is justified without it.

Stewardship that spares the gut

The goal is not zero opioids. Untreated severe pain wrecks sleep, work and marriages, and a taper forced onto pain that has never been treated is its own kind of harm. The goal is the lowest exposure that preserves function.

In our practice that follows a sequence. Interventional treatment aims at the structure generating the pain first, and the dose comes down as a consequence rather than a target. Arriving patients average more than 90 MME a day after more than two and a half years in pain. Under active interventional treatment, 21% are fully weaned within 90 days and 34% within one year. Across the established population, fewer than 1% remain above 90 MME. The figures are practice-reported, drawn from our own population rather than trial outcomes, and individual results vary.

For his bowel, that meant three moves: constipation onto the problem list, a plan aimed at the receptor instead of a fourth laxative, and a taper measured in months that began only once interventional work was underway. Behavioral care carries its share. Acceptance and Commitment Therapy, delivered in-house, helps a person tolerate the months of a taper, and rebuilding social contact removes an inflammatory load no pill touches. The arithmetic of a safe taper is its own subject.

The heartburn pill that rebounds when stopped set up this pattern of a drug that protects its own prescription, and the next post turns to a chemical nobody prescribed. For every study and every number behind these claims, including what each one cannot show, read the companion Deep Dive on the narcotic bowel.

Frequently asked questions

Does opioid-induced constipation go away over time?

Usually not. The body builds tolerance to the pain-relieving effect of opioids, but guideline reviews note that tolerance does not develop to the bowel effect, which persists and needs long-term management. That is why constipation often worsens as doses rise to chase pain. Treating it as a temporary nuisance leaves it untreated for years. The gut’s cleaning wave between meals is part of what stalls.

Why don’t stool softeners fix constipation from opioids?

A softener changes the stool, but the cause is the opioid receptor in the bowel wall, which keeps signaling for as long as the drug is present. A secretagogue that pulls water into the stool beat placebo modestly without improving quality of life. Drugs that block the gut receptor act on the cause, which is why newer guidance places them earlier. Morphine also tightens the door that bile passes through.

What is narcotic bowel syndrome?

It is abdominal pain that gets worse even as the opioid dose used to treat it holds steady or climbs. It develops in roughly 6% of long-term users and is thought to be driven by the central nervous system rather than the bowel, though it commonly travels with constipation. The direction of treatment is supervised reduction, not a higher dose. How to tell whether a medication is feeding your pain.

Will my pain get worse if my opioid dose is lowered?

Not necessarily, and often the opposite. Across the dose-reduction literature, the better-designed studies all found pain easing as doses fell, although overall certainty is very low. What makes it work is sequence: the source of the pain gets treated first, and the dose comes down slowly with your prescriber, never abruptly and never alone. Why medication is a bridge, not a destination.

Can opioids change the gut microbiome?

Early data suggest they can. In five opioid-agonist users in addiction treatment, microbial diversity was lower and two genera were depleted: Roseburia, which makes butyrate, and Bilophila, which handles bile acids. It is a very small sample, and people using a receptor blocker showed no such difference. A stool species list is not the same as what the microbiome is doing.

Sources

1. Sternini, C., Patierno, S., Selmer, I.-S., & Kirchgessner, A. (2004). The opioid system in the gastrointestinal tract. Neurogastroenterology and Motility, 16(Suppl 2), 3-16. https://doi.org/10.1111/j.1743-3150.2004.00553.x
2. Manabe, N., Ihara, E., Yomiya, K., Iseki, M., Torii, A., Miwa, H., & Camilleri, M. (2026). Current strategies and future perspectives in the management of opioid-induced constipation: A review of international and Japanese guidelines. Neurogastroenterology and Motility, 38(5), e70343. https://doi.org/10.1111/nmo.70343
3. Davies, A., Fagan, N., Gonzalez-Barboteo, J., Chelazzi, C., Economos, G., Elsner, F., Leach, C., Monsen, R. E., Oldenmenger, W. H., Remi, C., van den Beuken-van Everdingen, M., & Wüstefeld, M. (2024). Inadequate management of opioid-induced constipation in European cancer pain patients: Results of a real-world, multicentre, observational study (“E-StOIC”). Supportive Care in Cancer, 32(10), 701. https://doi.org/10.1007/s00520-024-08898-1
4. Bell, T. J., Panchal, S. J., Miaskowski, C., Bolge, S. C., Milanova, T., & Williamson, R. (2009). The prevalence, severity, and impact of opioid-induced bowel dysfunction: Results of a US and European patient survey (PROBE 1). Pain Medicine, 10(1), 35-42. https://doi.org/10.1111/j.1526-4637.2008.00495.x
5. Yimer, B. B., Soomro, M., McBeth, J., Medina, C. R. R., Lunt, M., Dixon, W. G., & Jani, M. (2025). Comparative risk of severe constipation in patients treated with opioids for non-cancer pain: A retrospective cohort study in Northwest England. BMC Medicine, 23(1), 288. https://doi.org/10.1186/s12916-025-04118-7
6. Hale, M., Wild, J., Reddy, J., Yamada, T., & Arjona Ferreira, J. C. (2017). Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): Two multicentre, phase 3, double-blind, randomised, parallel-group trials. The Lancet Gastroenterology & Hepatology, 2(8), 555-564. https://doi.org/10.1016/S2468-1253(17)30105-X
7. Luthra, P., Burr, N. E., Brenner, D. M., & Ford, A. C. (2019). Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: Systematic review and network meta-analysis. Gut, 68(3), 434-444. https://doi.org/10.1136/gutjnl-2018-316001
8. Jamal, M. M., Adams, A. B., Jansen, J.-P., & Webster, L. R. (2015). A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain. The American Journal of Gastroenterology, 110(5), 725-732. https://doi.org/10.1038/ajg.2015.106
9. Drossman, D., & Szigethy, E. (2014). The narcotic bowel syndrome: A recent update. American Journal of Gastroenterology Supplements, 2(1), 22-30. https://doi.org/10.1038/ajgsup.2014.6
10. Frank, J. W., Lovejoy, T. I., Becker, W. C., Morasco, B. J., Koenig, C. J., Hoffecker, L., Dischinger, H. R., Dobscha, S. K., & Krebs, E. E. (2017). Patient outcomes in dose reduction or discontinuation of long-term opioid therapy: A systematic review. Annals of Internal Medicine, 167(3), 181-191. https://doi.org/10.7326/M17-0598

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, board certified in anesthesiology, pain medicine, interventional pain management, addiction medicine and obesity medicine. Adapted from Chapter 21 of The Angry Gut by Dr. Padda and Ami Michelle Grimes. Last reviewed September 2026.

Dr. Gurpreet Singh Padda, MD, MBA, MHP